NewAmsterdam Pharma develops obicetrapib, an oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol. It last closed at $18.41 on Nov 20, down 5.64% on the day. The next earnings report for NAMS is expected around Wed, Feb 3, 2027. For the quarter ended Sep 2026, NAMS reported EPS of -$0.14 on revenue of $19.2M, with revenue up 5406.9% from a year ago. Over its last 8 reports the stock moved an average of 5.4% the session after earnings. Over the last 12 months NAMS insiders bought $227K of stock on the open market and sold $63.3M, according to SEC Form 4 filings.
AI Auto Pilots
Is NAMS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NAMS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NAMSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NAMS · as of the Nov 20 close · updated each morning
Downtrend
The stock is 7% below its 20 day and 15% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38). The nearest support is the 52 week low at $17.90, and the nearest resistance the Pivot at $18.82.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.0%/day
Key levels
$42.2052 week high+129.2%
$28.84200 day average+56.7%
$24.94100 day average+35.5%
$21.0950 day average+14.6%
$20.82Swing high (Nov 11)+13.1%
$19.7820 day average+7.4%
$19.36Pivot R1+5.2%
$18.82Pivot+2.2%
$18.41Last close
$17.9052 week low−2.8%
$17.90Swing low (Nov 9)−2.8%
$17.87Pivot S1−2.9%
Indicators
RSI (14)
38.44
Weak, oversold below 30
Neutral
MACD
-0.58
Above its signal line
Bullish
Stochastic
30.3
Middle of its range
Neutral
ADX (14)
13.4
No clear trend
Williams %R
-88.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-141.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−2.6%
Change over 10 sessions
Bearish
ATR (14)
$1.29
Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 17.1%/day
Key levels
$42.2052 week high+129.2%
$28.84200 day average+56.7%
$24.94100 day average+35.5%
$21.0950 day average+14.6%
$20.82Swing high (Nov 11)+13.1%
$19.7820 day average+7.4%
$19.36Pivot R1+5.2%
$18.82Pivot+2.2%
$18.41Last close
$17.9052 week low−2.8%
$17.90Swing low (Nov 9)−2.8%
$17.87Pivot S1−2.9%
Indicators
RSI (14)
31.58
Weak, oversold below 30
Neutral
MACD
-3.24
Below its signal line
Bearish
Stochastic
9.6
Near the bottom of its range
Oversold
ADX (14)
21.0
Weak trend
Williams %R
-95.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-97.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−19.3%
Change over 10 sessions
Bearish
ATR (14)
$3.14
Typical daily range, 17.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NAMS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NAMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NAMS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NAMSHow many large options trades hit NAMS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NAMS in the last 90 days.
From SEC Form 4 filings by NAMS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAMS is in one of them and how their past NAMS trades turned out.
NewAmsterdam Pharma is a biopharmaceutical company based in Naarden, Netherlands. It is developing obicetrapib, a once-a-day oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol who do not reach their targets on statins alone. The drug can be taken on its own or combined with ezetimibe, another cholesterol-lowering pill. The company plans to sell it in the United States itself and has given Menarini the rights to market it in most of Europe.